Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Denmark
/
Pharmaceuticals & Biotech
/
Novo Nordisk
NOVO B
Novo Nordisk
Urbanization And Aging Trends Will Amplify GLP-1 Adoption
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 21 Analysts
Published
30 May 25
Updated
08 Aug 25
9
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
DKK 761.00
57.4% undervalued
intrinsic discount
08 Aug
DKK 324.50
Loading
1Y
-65.0%
7D
5.1%
Author's Valuation
DKK 761.0
57.4% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
DKK 761.0
57.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
454b
2014
2017
2020
2023
2025
2026
2028
Revenue DKK 454.1b
Earnings DKK 170.6b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.58%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
DKK 170.63b
Earnings '28
x
22.66x
PE Ratio '28
=
DKK 3.87t
Market Cap '28
DKK 3.87t
Market Cap '28
/
4.40b
No. shares '28
=
DKK 878.71
Share Price '28
DKK 878.71
Share Price '28
Discounted to 2025 @ 4.92% p.a.
=
DKK 760.84
Fair Value '25